经皮免疫机制及其在过敏性疾病的应用进展

中华皮肤科杂志 ›› 2016, Vol. 49 ›› Issue (6): 441-444.

经皮免疫机制及其在过敏性疾病的应用进展

刘笑纯¹,姚煦²

1. 中国医学科学院北京协和医学院皮肤病研究所
2. 南京中国医学科学院北京协和医学院皮肤病研究所

收稿日期:2015-10-14 修回日期:2015-10-31 发布日期:2016-05-31
通讯作者: 姚煦 E-mail:dryao_xu@126.com
基金资助:
2014年亚美医学基金会（MMAAP）皮肤病项目基金资助;国家自然科学基金;国家自然科学基金;国家自然科学基金;江苏省自然科学基金

Mechanisms of transcutaneous immunization and its application in allergic diseases

Xiao-Chun LIU¹,

Received:2015-10-14 Revised:2015-10-31 Published:2016-05-31
Supported by:
;National Natural Science Foundation of China;National Natural Science Foundation of China;National Natural Science Foundation of China;Natural Science Foundation of Jiangsu Province

摘要/Abstract

摘要：

经皮免疫作为一种新型免疫治疗途径，是将抗原和佐剂局部应用于皮肤，诱导机体产生系统性免疫应答的接种方式，该方法安全有效，有望成为具有吸引力的传统疫苗替代途径。经皮免疫诱导不同方向免疫反应，但是皮肤免疫耐受方面的具体机制尚未完全明确。大多数研究基于动物模型，动物与人类皮肤存在结构差异，需建立更多研究实现动物模型向人体的转化。并非所有的疫苗都适用于皮肤接种，研究必须评估其安全性和有效性。各种改良的疫苗递送系统及其在相关疾病上的临床应用尚待进一步发掘。

Abstract:

Liu Xiaochun, Yao Xu Department of Allergy and Rheumatology, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China Corresponding author: Yao Xu, Email: dryao_xu@126.com 【Abstract】 Transcutaneous immunization （TCI） is a novel immunotherapy approach that induces systemic immune responses via topical application of antigens and adjuvants onto the skin. It is a safe and effective method, and is expected to serve as an attractive alternative to traditional vaccination. TCI induces immune responses in different directions, but the exact mechanism of skin immune tolerance is still unclear. Most studies on TCI are based on animal models. However, there are structural differences between animal skin and human skin, so more researches are needed to achieve the translation of TCI from bench to bedside. Not all vaccines are suitable for cutaneous inoculation, so vaccines for TCI should be evaluated for their safety and efficacy. Various reformed vaccine delivery systems are needed to be further explored in related diseases.

刘笑纯姚煦. 经皮免疫机制及其在过敏性疾病的应用进展[J]. 中华皮肤科杂志, 2016,49(6):441-444. doi:

Xiao-Chun LIU. Mechanisms of transcutaneous immunization and its application in allergic diseases[J]. Chinese Journal of Dermatology, 2016, 49(6): 441-444.doi:

参考文献 30

［1］	Wang LF, Lin JY, Hsieh KH, et al. Epicutaneous exposure of protein antigen induces a predominant Th2⁃like response with high IgE production in mice［J］. J Immunol, 1996, 156（11）: 4077⁃4082.
［2］	Glenn GM, Rao M, Matyas GR, et al. Skin immunization made possible by cholera toxin［J］. Nature, 1998, 391（6670）: 851.
［3］	Tay SS, Roediger B, Tong PL, et al. The skin⁃resident immune network［J］. Curr Dermatol Rep, 2014, 3（1）: 13⁃22.
［4］	Jang S, Park JS, Won YH, et al. The of toll⁃like receptors （TLRs） in cultured human skin fibroblast is modulated by histamine［J］. Chonnam Med J, 2012, 48（1）: 7⁃14. DOI: 10.4068/cmj.2012.48.1.7.
［5］	Igyártó BZ, Haley K, Ortner D, et al. Skin⁃resident murine dendritic cell subsets promote distinct and opposing antigen⁃specific T helper cell responses［J］. Immunity, 2011, 35（2）: 260⁃272. DOI: 10.1016/j.immuni.2011.06.005.
［6］	Kumamoto Y, Linehan M, Weinstein JS, et al. CD301b+ dermal dendritic cells drive T helper 2 cell⁃mediated immunity［J］. Immunity, 2013, 39（4）: 733⁃743. DOI: 10.1016/j.immuni.2013.08. 029.
［7］	Nakajima S, Igyarto BZ, Honda T, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling［J］. J Allergy Clin Immunol, 2012, 129（4）: 1048⁃1055. DOI: 10.1016/j.jaci.2012.01.063.
［8］	Strid J, Sobolev O, Zafirova B, et al. The intraepithelial T cell response to NKG2D⁃ligands links lymphoid stress surveillance to atopy［J］. Science, 2011, 334（6060）: 1293⁃1297. DOI: 10.1126/science.1211250.
［9］	Otsuka A, Kubo M, Honda T, et al. Requirement of interaction between mast cells and skin dendritic cells to establish contact hypersensitivity［J］. PLoS One, 2011, 6（9）: e25538. DOI: 10.1371/journal.pone.0025538.
［10］	Novak N, Bieber T. 2. Dendritic cells as regulators of immunity and tolerance［J］. J Allergy Clin Immunol, 2008, 121（2 Suppl）: S370⁃S374, S413. DOI: 10.1016/j.jaci.2007.06.001.
［11］	Gomez De Agüero M, Vocanson M, Hacini⁃Rachinel F, et al. Langerhans cells protect from allergic contact dermatitis in mice by tolerizing CD8+ T cells and activating Foxp3+ regulatory T cells［J］. J Clin Invest, 2012, 122（5）: 1700⁃1711. DOI: 10.1172/JCI59725.
［12］	Seneschal J, Clark RA, Gehad A, et al. Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells［J］. Immunity, 2012, 36（5）: 873⁃84. DOI: 10.1016/j.immuni.2012.03.018.
［13］	Shklovskaya E, O′Sullivan BJ, Ng LG, et al. Langerhans cells are precommitted to immune tolerance induction［J］. Proc Natl Acad Sci U S A, 2011, 108（44）: 18049⁃18054. DOI: 10.1073/pnas.1110076108.
［14］	Rattanapak T, Birchall JC, Young K, et al. Dynamic visualization of dendritic cell⁃antigen interactions in the skin following transcutaneous immunization［J］. PLoS One, 2014, 9（2）: e89503. DOI: 10.1371/journal.pone.0089503.
［15］	Engelke L, Winter G, Hook S, et al. Recent insights into cutaneous immunization: How to vaccinate via the skin［J］. Vaccine, 2015, 33（37）: 4663⁃74. DOI: 10.1016/j.vaccine.2015.05.012.
［16］	Mittal A, Raber AS, Lehr CM, et al. Particle based vaccine formulations for transcutaneous immunization［J］. Hum Vaccin Immunother, 2013, 9（9）: 1950⁃5. DOI: 10.4161/hv.25217.
［17］	Matsuo K, Ishii Y, Quan YS, et al. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat［J］. J Control Release, 2011, 149（1）: 15⁃20. DOI: 10.1016/j.jconrel.2010.05.012.
［18］	Mazzitelli S, Pagano C, Giusepponi D, et al. Hydrogel blends with adjustable properties as patches for transdermal delivery［J］. Int J Pharm, 2013, 454（1）: 47⁃57. DOI: 10.1016/j.ijpharm.2013.06.081.
［19］	Sloat BR, Kiguchi K, Xiao G, et al. Transcutaneous DNA immunization following waxing⁃based hair depilation［J］. J Control Release, 2012, 157（1）: 94⁃102. DOI: 10.1016/j.jconrel.2011.08.038.
［20］	Mittal A, Raber AS, Schaefer UF, et al. Non⁃invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization［J］. Vaccine, 2013, 31（34）: 3442⁃3451. DOI: 10.1016/j.vaccine.2012.12.048.
［21］	Hessenberger M, Weiss R, Weinberger EE, et al. Transcutaneous delivery of CpG⁃adjuvanted allergen via laser⁃generated micropores［J］. Vaccine, 2013, 31（34）: 3427⁃3434. DOI: 10.1016/j.vaccine.2012.09.086.
［22］	Zaric M, Lyubomska O, Poux C, et al. Dissolving microneedle delivery of nanoparticle⁃encapsulated antigen elicits efficient cross⁃priming and Th1 immune responses by murine Langerhans Cells［J］. J Invest Dermatol, 2015, 135（2）: 425⁃34. DOI: 10.1038/jid.2014.415.
［23］	Li N, Peng L, Chen X, et al. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers［J］. Vaccine, 2011, 29（37）: 6179⁃6190. DOI: 10.1016/j.vaccine.2011. 06.086.
［24］	Senti G, von Moos S, Kündig TM. Epicutaneous immunotherapy for aeroallergen and food allergy［J］. Curr Treat Options Allergy, 2014, 1（1）: 68⁃78.
［25］	Senti G, von Moos S, Tay F, et al. Epicutaneous allergen⁃specific immunotherapy ameliorates grass pollen⁃induced rhinoconjunc⁃tivitis: a double⁃blind, placebo⁃controlled dose escalation study［J］. J Allergy Clin Immunol, 2012, 129（1）: 128⁃135. DOI: 10.1016/j.jaci.2011.08.036.
［26］	Agostinis F, Forti S, Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis［J］. Allergy, 2010, 65（3）: 410⁃411. DOI: 10.1111/j.1398⁃9995.2009. 02189.x.
［27］	田阳子, 李巍, 刘玉峰. 卵清蛋白经皮诱导免疫耐受机制初探［J］.中国皮肤性病学杂志, 2011（08）: 601⁃603.
	Tian YZ, Li W, Liu YF. Immune tolerance induced by application of antigen onto intact skin and its mechanism［J］. Chin J Derm Venereol, 2011（08）: 601⁃603.
［28］	Bach D, Weiss R, Hessenberger M, et al. Transcutaneous immu⁃notherapy via laser⁃generated micropores efficiently alleviates allergic asthma in Phl p 5⁃sensitized mice［J］. Allergy, 2012, 67（11）: 1365⁃1374. DOI: 10.1111/all.12005.
［29］	Garaczi E, Szabo K, Francziszti L, et al. DermAll nanomedicine for allergen⁃specific immunotherapy［J］. Nanomedicine, 2013, 9（8）: 1245⁃1254. DOI: 10.1016/j.nano.2013.05.011.
［30］	Weiss R, Scheiblhofer S, Machado Y, et al. New approaches to transcutaneous immunotherapy: targeting dendritic cells with novel allergen conjugates［J］. Curr Opin Allergy Clin Immunol, 2013, 13（6）: 669⁃676. DOI: 10.1097/ACI.0b013e328364f4df.